JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2015, Vol. 53 ›› Issue (5): 1-4.doi: 10.6040/j.issn.1671-7554.2.2015.001

    Next Articles

Immune-regulation of statins in atherosclerosis and opinions on its clinical applications

DUAN Ruisheng   

  1. Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, Shandong, China
  • Received:2015-02-24 Revised:2015-04-07 Online:2015-05-10 Published:2015-05-10

PDF (PC)

163

Abstract: It has been demonstrated that the pathogenesis of atherosclerosis is characteristic of inflammation and immune responses, which includes innate and adaptive immune responses to oxidative lipoprotein. The immune cells in the atherosclerotic plaque include macrophages, CD4+ and CD8+ T cells, B cells, dendritic cells, regulatory T cells, NK cells, neurophils and mast cells. Statins have anti-inflammatory and immune suppressive roles and have been applied in the treatment of autoimmune diseases. The statin benefit observed in the atherosclerosis is due to both lipid-lowing and anti-inflammatory effects. Hypersensitive C-reactive protein (hsCRP), an inflammatory marker of atherosclerosis, and low-density lipoprotein cholesterol (LDL-C) are equally strong predictors of cardiovascular risk. Both LDL-C and hsCRP should be monitored in the prevention and treatment of atherosclerosis.

Key words: Immune responses, Atherosclerosis, Statins, Hypersensitive C-reactive protein

CLC Number: 

  • R543.5
[1] Witztum JL, Lichtman AH. The influence of innate and adaptive immune responses on atherosclerosis[J]. Annu Rev Pathol, 2014(9):73-102.
[2] Hansson GK, Hermansson A. The immune system in atherosclerosis[J]. Nat Immunol, 2011, 12(3):204-212.
[3] Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options[J]. Nat Med, 2011, 17(11):1410-1422.
[4] Sigal LH. Basic science for the clinician 44: atherosclerosis: an immunologically mediated (autoimmune?) disease[J]. J Clin Rheumatol, 2007, 13(3):160-168.
[5] Sakakura K, Nakano M, Otsuka F, et al. Pathophysiology of atherosclerosis plaque progression[J]. Heart Lung Circ, 2013, 22(6):399-411.
[6] Bu DX, Griffin G, Lichtman AH. Mechanisms for the anti-inflammatory effects of statins[J]. Curr Opin Lipidol, 2011, 22(3):165-170.
[7] Chalubinski M, Broncel M. Influence of statins on effector and regulatory immune mechanisms and their potential clinical relevance in treating autoimmune disorders[J]. Med Sci Monit, 2010, 16(11):RA245-251.
[8] Weber MS, Zamvil SS. Statins and demyelination[J]. Curr Top Microbiol Immunol, 2008, 318:313-324.
[9] Li XL, Dou YC, Liu Y, et al. Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells[J]. Cell Immunol, 2011, 271(2):455-461.
[10] Forero-Pena DA, Gutierrez FR. Statins as modulators of regulatory T-cell biology[J]. Mediators Inflamm, 2013, 2013:167086. doi: 10.1155/2013/167086.
[11] Li XL, Liu Y, Cao LL, et al. Atorvastatin-modified dendritic cells in vitro ameliorate experimental autoimmune myasthenia gravis by up-regulated Treg cells and shifted Th1/Th17 to Th2 cytokines[J]. Mol Cell Neurosci, 2013, 56:85-95. doi: 10.1016/j.mcn.2013.03.005.
[12] Xu H, Li XL, Yue LT, et al. Therapeutic potential of atorvastatin-modified dendritic cells in experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells and NKR-P1(+) cells[J]. J Neuroimmunol, 2014, 269(1-2):28-37.
[13] Khattri S, Zandman-Goddard G. Statins and autoimmunity[J]. Immunol Res, 2013, 56(2-3):348-357.
[14] Wang J, Xiao Y, Luo M, et al. Statins for multiple sclerosis[J]. Cochrane Database Syst Rev, 2010, 2010(12):CD008386. doi:10.1002/14651858.CD008386.pub2.
[15] Meng X, Zhang K, Li J, et al. Statins induce the accumulation of regulatory T cells in atherosclerotic plaque[J]. Mol Med, 2012(18):598-605. doi: 10.2119/molmed.2011.00471.
[16] Everett BM, Glynn RJ, MacFadyen JG, et al. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)[J]. Circulation, 2010, 121(1):143-150.
[17] Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J]. N Engl J Med, 2008, 359(21):2195-2207.
[18] Ridker PM. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?[J]. Curr Atheroscler Rep, 2013, 15(1):295.
[19] Ridker PM,Silvertown JD. Inflammation, C-reactive protein, and atherothrombosis[J]. J Periodontol, 2008, 79(8 Suppl):1544-1551.
[20] Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial[J]. Circulation, 2006, 114(4):281-288.
[21] Ridker PM. Inflammation, C-reactive protein, and cardiovascular disease: moving past the marker versus mediator debate[J]. Circ Res, 2014, 114(4):594-595.
[22] Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adul-2009 recommendations[J]. Can J Cardiol, 2009, 25(10):567-579.
[23] Ridker PM, Kastelein JJ, Genest J, et al. C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care[J]. Eur Heart J, 2013, 34(17):1258-1261.
[1] XU Ning-Yu, WANG Lei, HAO En-Kui, SU Guo-Hai. Effects of atorvastatin given before acute PCI on inflammatory mediators and left ventricular function in STEMI [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 69-72.
[2] FU Jieqi, ZHANG Man, ZHANG Xiaolu, LI Hui, CHEN Hong. Molecular mechanism of Toll-like receptor 4 in the aggravation of blood lipid accumulation by inhibiting the peroxisome proliferator-activate receptor γ [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 24-31.
[3] YIN Ni, YANG Guanlin, JIANG Junwen, WANG Chuntian, WANG Fengyao, JIA Lianqun, GAO Xiaoyu, PAN Jiaxiang, LI Qin, LI Jia, FENG Yuanjie, GAO Yuzhu, ZHOU He, ZHANG Zhe. A reliable system to assess atherosclerosis model of Bama minipigs [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 1-5.
[4] WEI Dandan, ZHANG Cheng. Effects of the overexpression of type 4 angiotensin receptor on the formation of atherosclerotic lesions [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(8): 1-5.
[5] WANG Dan, QI Hengtao, SUN Shuzhen. Changes of carotid artery structure and function in children with primary nephrotic syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(5): 88-91.
[6] SUN Pengfei, MENG Xiao, ZHANG Kai, LI Li. The effect of resistin-like molecule β on the vulnerability of atherosclerotic plaques in ApoE-/- mice [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 1-4.
[7] WANG Xiaofei, WANG Chengwei, WANG Zhigang, DING Xuan, WANG Minqing. Application of enterprise stent in atherosclerotic vertebral-basilar arterial stenosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(8): 44-48.
[8] YU Xin, LIU Xiaojing, LIU Xiangqun. The inhibitory effect of baicalin on endothelial cell apoptosis induced by ox-LDL [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(5): 5-9.
[9] TAN Bei, GUAN Yuqing, SUN Hui, HU Keqing, SU Guohai, WEI Min. Effects of atorvastatin with intravascular ultrasound on atherosclerotic plaques in rabbits [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(5): 10-14.
[10] YU Lei, LI Zhen. Expression of interleukin-33 and its function in the serum of patients with cerebrovascular disease [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(4): 75-79.
[11] XU Zhongyang, WANG Liqi, XU Zhenxing, ZHAO Qian, ZHU Shiming. Correlations among RhoA/ROCK signaling pathway, blood pressure variability and carotid artery intima-media thickness in essential hypertensive patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(2): 48-51.
[12] RONG Chunli, YAO Wenjing, YANG Qian, LI Ruyi, CAO Dongping, LIU Meixia, PENG Yingxin. Clinical efficacy of atorvastatincalcium combined with ezetimibe in the treatment of coronary atherosclerosis with hyperlipidemia [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(11): 46-49.
[13] JIN Chengwei, LI Kui, ZHAO Jing, YUE Xin, SHANG Yuanyuan, HAN Lu, ZHANG Yun, ZHANG Wei, MA Xiao, ZHONG Ming. Relationship between the mRNA expression of adipose triglyceride lipase in peripheral blood mononuclear cells and metabolic syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(8): 39-42.
[14] LI Yueyan1, GUAN Yuqing2, MIAO Wei2, HU Keqing2, HU Hongyan3, LI Ying2, WANG Xiaoqi2, SU Guohai2. Effect of atorvastatin on TLR4 expression and downstream signaling in atherosclerotic rabbits [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(6): 1-6.
[15] HAO Fengcheng1,2, SU Zhonghua1,3. Protective effect of autophagy on the inflammation induced by ox-LDL [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(4): 30-34.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd